Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2006;99:1419-1425
Published online before print November 2, 2006, doi: 10.1161/01.RES.0000251741.65179.56
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
99/12/1419    most recent
01.RES.0000251741.65179.56v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asleh, R.
Right arrow Articles by Levy, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asleh, R.
Right arrow Articles by Levy, A. P.
Related Collections
Right arrow Lipid and lipoprotein metabolism
Right arrow Oxidant stress
Right arrow Type 2 diabetes
Right arrow Pathophysiology
Right arrow Genetically altered mice
(Circulation Research. 2006;99:1419.)
© 2006 American Heart Association, Inc.


Clinical Research

Haptoglobin Genotype Is a Regulator of Reverse Cholesterol Transport in Diabetes In Vitro and In Vivo

Rabea Asleh, Rachael Miller-Lotan, Michael Aviram, Tony Hayek, Michael Yulish, Joanne E. Levy{dagger}, Benjamin Miller, Shany Blum, Uzi Milman, Chen Shapira, Andrew P. Levy

From the Rappaport Faculty of Medicine (R.A., R.M.-L., M.A., S.B., A.P.L.), Technion-Israel Institute of Technology, Haifa, Israel; Departments of Internal Medicine (T.H.) and Opthalmology (M.Y., B.M.), Rambam Medical Center, Haifa, Israel; Department of Hematology and Oncology (J.E.L.), Brigham and Women’s Hospital, Boston, Mass; and Clinical Research Unit (U.M., C.S.), Clalit Health Services, Haifa and Western Galilee, Israel.

Correspondence to Dr Andrew P. Levy, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, POB 9649, Haifa 31096, Israel. E-mail alevy{at}tx.technion.ac.il

Two common alleles exist at the haptoglobin (Hp) locus, and the Hp2 allele is associated with an increased incidence of cardiovascular disease, specifically in diabetes mellitus (DM). Oxidative stress is increased in Hp2 mice and humans with DM. Oxidative modification of the apolipoprotein A-I inhibits reverse cholesterol transport. We sought to test the hypothesis that reverse cholesterol transport is impaired in Hp2 DM mice and humans. In vitro, using serum from non-DM and DM individuals, we measured cholesterol efflux from 3H-cholesterol–labeled macrophages. In vivo, we injected 3H-cholesterol–loaded macrophages intraperitoneally into non-DM and DM mice with the Hp1-1 or Hp2-2 genotype and monitored 3H-tracer levels in plasma, liver, and feces. In vitro, in DM individuals only, we observed significantly decreased cholesterol efflux from macrophages incubated with serum from Hp2-1 or Hp2-2 as compared with Hp1-1 individuals (P<0.01). The interaction between Hp type and DM was recapitulated using purified Hp and glycated Hb. In vivo, DM mice loaded with 3H-cholesterol–labeled macrophages had a 40% reduction in 3H-cholesterol in plasma, liver, and feces as compared with non-DM mice (P<0.01). The reduction in reverse cholesterol transport associated with DM was significantly greater in Hp2-2 mice as compared with Hp1-1 mice (54% versus 25% in plasma; 52% versus 27% in liver; 57% versus 32% in feces; P<0.03). reverse cholesterol transport is decreased in Hp2-2 DM. This may explain in part the increased atherosclerotic burden found in Hp2-2 DM individuals.


Key Words: diabetes mellitus • haptoglobin polymorphism • high-density lipoprotein • reverse cholesterol transport • oxidative stress




This article has been cited by other articles:


Home page
DiabetesHome page
T. Costacou, R. E. Ferrell, and T. J. Orchard
Haptoglobin Genotype: A Determinant of Cardiovascular Complication Risk in Type 1 Diabetes
Diabetes, June 1, 2008; 57(6): 1702 - 1706.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
U. Milman, S. Blum, C. Shapira, D. Aronson, R. Miller-Lotan, Y. Anbinder, J. Alshiek, L. Bennett, M. Kostenko, M. Landau, et al.
Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype: A Prospective Double-Blinded Clinical Trial
Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 341 - 347.
[Abstract] [Full Text] [PDF]